Experimental mitochondrial vaccine targets Hard-to-Treat cancers
NCT ID NCT06927297
First seen Mar 22, 2026 · Last updated May 24, 2026 · Updated 7 times
Summary
This early-stage trial tests a new type of vaccine made from engineered mitochondria (the cell's powerhouses) that carry a tumor-specific antigen. It is for people with advanced solid tumors like lung or colorectal cancer who have no other good treatment options. The main goal is to see if the vaccine is safe and tolerable, and to get an early look at whether it can shrink or control tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR MALIGNANCIES are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
West China Hospital, Sichuan University
RECRUITINGChengdu, Sichuan, 610041, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.